+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

US Preventive Inhaler Market 2019-2025

  • PDF Icon

    Report

  • January 2020
  • Region: United States
  • Orion Market Research Private Limited
  • ID: 4991513
UP TO OFF until Dec 31st 2022
US Preventive Inhaler Market Size, Share & Trends Analysis Report by Device Type (Metered Dose Inhaler and Dry Powdered Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

US preventive inhaler market is anticipated to grow at a substantial rate of 1.2% during the forecast period. The growth of the market of preventive inhalers in the US is mainly driven by factors that include the growing prevalence of chronic diseases such as asthma, diabetes, respiratory lung diseases and so on. Asthma is chronic inflammation of the lung airways that causes breathlessness and coughing. The number of people with asthma grows every year in the US. According to CDC, there are around 26 million asthma patients in the US, among which, nearly 18.9 million are adults and 7.1 million are children. Moreover, the prevalence of asthma in children is nearly 9.4% which is higher than that of adults accounting to around 7.7%, and higher in females nearly 9.2% than in males accounting to 7% of total asthma patients. This is one of the primary reasons for the high growth rate of the market within the country.

The US preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of device, the market is sub-segmented into metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have the largest market share in the US preventive inhaler market due to providing an easy inhalation solution. Whereas, the market for metered dose inhaler is estimated to be the fastest-growing at a CAGR during the forecast period owing to innovations and collaborations by the companies for the development of metered dosed inhaler. Based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing inhalers to cater to a wide range of customers within the region and across the globe. The major players of the US preventive inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp. (Propeller Health), Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the US preventive inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:
1. US Preventive Inhaler Market Research and Analysis by Device Type
2. US Preventive Inhaler Market Research and Analysis by Application
3. US Preventive Inhaler Market Research and Analysis by End-User
The Report covers:
  • Comprehensive research methodology of the US preventive inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the US preventive inhaler market.
  • Insights about market determinants which are stimulating the US preventive inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. US Preventive Inhaler Market by Device Type
5.1.1. Metered Dose Inhaler
5.1.2. Dry Powder Inhaler
5.2. US Preventive Inhaler Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. US Preventive Inhaler Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics
6. Company Profiles
6.1. 3M Co.
6.2. Acorda Therapeutics, Inc.
6.3. Adamis Pharmaceuticals Corp.
6.4. Adherium Ltd.
6.5. Aradigm Corp.
6.6. AstraZeneca PLC
6.7. Boehringer Ingelheim International GmbH
6.8. Drive Devilbiss Healthcare LLC
6.9. GlaxoSmithKline PLC
6.10. Koninklijke Philips N.V.
6.11. Manta Devices LLC
6.12. Novartis AG
6.13. Omron Healthcare Inc.
6.14. ResMed Corp.
6.15. Pulmatrix Inc.
6.16. Savara, Inc.
6.17. Sunovion Pharmaceuticals
6.18. Teva Pharmaceuticals Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3M Co.
  • Acorda Therapeutics, Inc.
  • Adamis Pharmaceuticals Corp.
  • Adherium Ltd.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Drive Devilbiss Healthcare LLC
  • GlaxoSmithKline PLC
  • Koninklijke Philips N.V.
  • Manta Devices LLC
  • Novartis AG
  • Omron Healthcare Inc.
  • ResMed Corp.
  • Pulmatrix Inc.
  • Savara, Inc.
  • Sunovion Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.